Trials / Conditions / Stage IVA Oropharyngeal Squamous Cell Carcinoma

Stage IVA Oropharyngeal Squamous Cell Carcinoma

12 registered clinical trials studyying Stage IVA Oropharyngeal Squamous Cell Carcinoma.

Status	Trial	Sponsor	Phase
Completed	Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell NCT03422536	University of Arizona	Phase 2
Completed	Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carc NCT03342911	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	Phase 2
Completed	Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer CaregiversHead and Neck Can NCT03032250	Wake Forest University Health Sciences	N/A
Terminated	Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer NCT02827838	Wake Forest University Health Sciences	EARLY_Phase 1
Terminated	Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer NCT02388932	Case Comprehensive Cancer Center	N/A
Terminated	Ganetespib Window of Opportunity Study in Head and Neck Cancers NCT02334319	Emory University	Phase 1
Completed	Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advance NCT02254278	NRG Oncology	Phase 2
Terminated	Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Ne NCT02196168	National Cancer Institute (NCI)	Phase 2
Completed	Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer NCT01932697	Mayo Clinic	Phase 2
Terminated	Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer NCT01267240	National Cancer Institute (NCI)	Phase 2
Completed	Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who D NCT01256385	National Cancer Institute (NCI)	Phase 2
Completed	Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer NCT02007200	National Cancer Institute (NCI)	Phase 2